Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Implementing an Evidence-based Alcohol Use and Sexual Risk Intervention in Young Adult Homeless Service Settings

6 de novembro de 2026 atualizado por: Graham DiGuiseppi, RAND

The goal of this clinical trial is to learn if AWARE-a brief, 4-session group program based on motivational interviewing-reduces alcohol and other drug use and sexual risk behavior among young adults experiencing homelessness (ages 18-25). The study will also learn how well AWARE can be delivered in real-world drop-in center settings and what it would take to keep the program running long-term.

The main questions it aims to answer are:

  • Does AWARE reduce the frequency, quantity, and consequences of alcohol use more than services as usual?
  • Does AWARE reduce sexual risk behavior (condomless sex with primary and casual partners, number of sexual partners, and alcohol or other drug use during sexual activity)?
  • How consistently and well can AWARE be delivered at community drop-in centers?

Researchers will compare AWARE to services as usual at three drop-in centers in Los Angeles and Pittsburgh to see if AWARE works to better.

Participants will:

  • Attend up to 4 group sessions of AWARE or continue receiving usual services at their drop-in center
  • Complete surveys about their alcohol and drug use, sexual behavior, and health at study enrollment, and 3 and 6 month follow-ups.

Visão geral do estudo

Descrição detalhada

Young adults experiencing homelessness (YAEH) are disproportionately affected by alcohol and other drug (AOD) use and sexual risk behavior, yet drop-in centers serving this population have limited access to brief, evidence-based programs that address both. AWARE is a 4-session group intervention grounded in motivational interviewing (MI) that targets AOD use and sexual risk behavior among 18-25 year olds experiencing homelessness. The program integrates education, skills building, and normative feedback in an interactive group format, incorporating components shown to be effective with homeless youth and other at-risk populations: enhancing protective factors, targeting multiple risk behaviors together, using active learning techniques, reinforcing skills, and delivering information in a non-judgmental manner. Sessions address HIV/STI knowledge and partner risk evaluation (Session 1), identifying and managing triggers for sexual risk behavior (Session 2), weighing the pros and cons of substance use and building strategies to reduce harm (Session 3), and understanding how AOD use affects brain functioning and behavior (Session 4). The brief format and group delivery model were designed to fit the service realities of drop-in centers, where YAEH may engage sporadically and staff capacity is limited.

The study design is a hybrid type 1 effectiveness-implementation study in which we will test the effectiveness of AWARE on young adult health outcomes, while collecting contextual data on implementation and sustainability of the intervention. The effectiveness study will follow a group-randomized design in which young adults receiving services at three drop-in centers will either be in the intervention condition (N = 180) or a services as usual control condition (N = 180). Young adult participants will complete surveys measuring primary and secondary outcomes at baseline, and follow-up surveys at 3- and 6-months post-baseline. The group-randomized trial will have crossover conditions and groups to avoid problems of power reduction and contamination associated with conventional group randomization. The unit of analysis will be the individual, but individuals will be assigned to groups based on where they receive services at a given time. The field period in each condition will be divided into four 22-week phases. The three drop-in centers will alternate serving as the "intervention site" or the "control site," with each center having two intervention phases and two control phases. The first 16 weeks of each phase involves delivering AWARE (intervention sites) or surveying participants at the control sites. Sixteen weeks was chosen to repeat the four-session AWARE program four times, allowing YAEH several opportunities to attend all sessions. The remaining six weeks of each phase is an inactive "wash out" period to allow for the recruitment of a new cohort and reduce the likelihood of contamination across conditions.

In addition to testing effectiveness, this study will assess how consistently and with what quality AWARE is delivered across sites and phases (implementation outcomes), and what organizational and fiscal conditions would support long-term sustainment. Fidelity to the AWARE protocol and MI will be assessed by audio recording sessions and rating them using an adherence checklist. Participant perspectives on intervention quality will be captured at the 3-month follow-up via item measuring therapeutic alliance and MI-consistent facilitator behaviors. Sustainment will be examined through interviews with policy actors and site leaders to identify barriers and facilitators to continued adoption beyond the study period.

Tipo de estudo

Intervencional

Inscrição (Estimado)

360

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Marylou Gilbert
  • Número de telefone: 6007 310-393-0411
  • E-mail: marylou@rand.org

Locais de estudo

    • California
      • Los Angeles, California, Estados Unidos, 90028
      • Venice, California, Estados Unidos, 90291
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15222
        • 412 Youth Zone
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 25 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • aged 18-25 years
  • receiving services at the drop-in center
  • plans to stay in the geographic area for the next month
  • English speaking

Exclusion Criteria:

  • Observed cognitive impairment during enrollment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: AWARE condition

AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback. Participants will have access to all usual care services while receiving AWARE.

AWARE is a brief (four-session) group counseling intervention that uses motivational interviewing and psychoeducation to address hazardous alcohol use and sexual risk behaviors. AWARE was developed with input from young adults experiencing homelessness and service providers and has shown to be feasible, acceptable, and efficacious when delivered in young adult homeless service settings. AWARE sessions are 45-minutes in length and delivered by one to two facilitators who receive training on the AWARE protocol and motivational interviewing. AWARE sessions provide normative feedback about alcohol use, and education about sexual risk behaviors and sexually transmitted infections. AWARE is designed to be collaborative and strengths-based, helping young adults identify and plan for high-risk situations and develop effective coping strategies to reduce the likelihood of alcohol-related negative consequences and sexual risk behaviors.

Sem intervenção: Standard care condition

Participants in the Standard Care condition have access to "usual care" at the drop-in center where the study is being conducted.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Alcohol use frequency
Prazo: Baseline, 3 months, and 6 months follow-up

The number of alcohol use days (any alcohol use) and the number of binge drinking days (5+ drinks) in the past 30 days

Baseline, 3 months, and 6 months follow-up
Alcohol use quantity
Prazo: Baseline, 3 months, and 6 months follow-up

The typical number of drinks consumed on drinking days, and the maximum number of drinks consumed on drinking days in the past 30 days

Baseline, 3 months, and 6 months follow-up
Alcohol use consequences
Prazo: Baseline, 3 months, and 6 months follow-up

Number of alcohol consequences in the past 30 days, assessed by the Brief Young Adult Alcohol Consequences Questionnaire (BYAACQ)

Baseline, 3 months, and 6 months follow-up

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Other drug use frequency
Prazo: Baseline, 3 months, and 6 months follow-up

Number of days of other drug use besides alcohol (cannabis, stimulants, opioids, sedatives/barbiturates, hallucinogens, cigarette and vape use) in the past 30 days.

Baseline, 3 months, and 6 months follow-up
Cannabis use quantity
Prazo: Baseline, 3 months, and 6 months follow-up

Amount of flower/bud consumed (in grams) on a typical cannabis use day

Baseline, 3 months, and 6 months follow-up
Cannabis use consequences
Prazo: Baseline, 3 months, and 6 months follow-up

Number of cannabis use consequences in the past 30 days, measured by the Brief-Marijuana Consequences Questionnaire (B-MACQ)

Baseline, 3 months, and 6 months follow-up
Substance use disorder
Prazo: Baseline, 3 months, and 6 months follow-up

Probable substance use disorder, measured with the Global Appraisal of Individual Needs Short Screener (GAIN-SS)

Baseline, 3 months, and 6 months follow-up
Number of sexual partners
Prazo: Baseline, 3 months, and 6 months follow-up

Number of oral, vaginal and anal sex partners in the past 3 months. Primary and casual sex partners will be reported separately.

Baseline, 3 months, and 6 months follow-up
Condom use
Prazo: Baseline, 3 months, and 6 months follow-up

Percentage of oral, vaginal, and anal sex events in which a condom was used in the past 3 months, assessed separately for primary and casual partners

Baseline, 3 months, and 6 months follow-up
Alcohol or other drug use during sexual activity
Prazo: Baseline, 3 months, and 6 months follow-up

Frequency of alcohol or other drug use before or during sex in the past 3 months (0=Never to 4=Every time), with primary and casual partners

Baseline, 3 months, and 6 months follow-up
Perceived importance of condom use
Prazo: Baseline, 3 months, and 6 months follow-up

Importance of increasing condom use during sex, or remaining a consistent condom user, measured on a scale from 0 (not at all important) to 10 (extremely important).

Baseline, 3 months, and 6 months follow-up
Condom use self-efficacy
Prazo: Baseline, 3 months, and 6 months follow-up

Self-efficacy to use a condom correctly and consistently and to discuss condom use with partners (from "not at all sure" to "very sure"), assessed using 8-items from a scale by Brafford and Beck (1991)

Baseline, 3 months, and 6 months follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Graham DiGuiseppi, RAND
  • Investigador principal: Ariella Korn, RAND

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de abril de 2027

Conclusão Primária (Estimado)

30 de setembro de 2029

Conclusão do estudo (Estimado)

30 de setembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

6 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de novembro de 2026

Primeira postagem (Real)

12 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualitative data to be shared include de-identified transcripts generated from staff focus groups and interviews with policy actors. Data will be made available to researchers for secondary analysis or replication of study findings. Transcripts will be de-identified, and sites will be referred to as Site 1, Site 2, and Site 3.

Quantitative data to be shared include de-identified, aggregate survey data to be made available for secondary analysis or replication of study findings. A separate ASCII (csv) data file will be created for young adult demographic and health outcomes (Aim 1), cost and cost-effectiveness data (Aim 1), participant reach and acceptability (Aim 2), AWARE fidelity ratings (Aim 2), and implementation outcomes (Aim 2).

Prazo de Compartilhamento de IPD

We will deposit study data in the National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) repository starting 12 months after the award begins. Study protocols, metadata, and de-identified data sets that are ready for public use will be submitted semi-annually (twice per year). Clinical trial data will be shared after the clinical trial is completed. Final project data will be made available at time of manuscript publication, or within 12 months following the project end date, whichever comes first.

Critérios de acesso de compartilhamento IPD

Data will be findable for the research community through the NIAAADA. The study will be findable and identifiable using unique URL links. Links to public access files will be shared in all peer-reviewed publications.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever